Cargando…

Reframing quercetin as a promiscuous inhibitor against SARS-CoV-2 main protease

Detalles Bibliográficos
Autores principales:	Yan, Haohao, Zhang, Rui, Liu, Xiaoping, Wang, Yanchang, Chen, Yunyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	National Academy of Sciences 2023
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500161/ https://www.ncbi.nlm.nih.gov/pubmed/37669361 http://dx.doi.org/10.1073/pnas.2309289120

Ejemplares similares

Protocol for high-throughput screening of SARS-CoV-2 main protease inhibitors using a robust fluorescence polarization assay
por: Zhang, Jing, et al.
Publicado: (2022)

A robust high-throughput fluorescence polarization assay for rapid screening of SARS-CoV-2 papain-like protease inhibitors
por: Yan, Haohao, et al.
Publicado: (2022)

Reply to Yan et al.: Quercetin possesses a fluorescence quenching effect but is a weak inhibitor against SARS-CoV-2 main protease
por: Xu, Haiyu, et al.
Publicado: (2023)

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
por: Zhao, Yao, et al.
Publicado: (2021)

Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors
por: Ma, Chunlong, et al.
Publicado: (2020)

Ginkgolic acid and anacardic acid are reversible inhibitors of SARS-CoV-2 3-chymotrypsin-like protease
por: Li, Dongsheng, et al.
Publicado: (2022)

Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors
por: Ma, Chunlong, et al.
Publicado: (2020)

Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′s main protease
por: Mahdi, Mohamed, et al.
Publicado: (2020)

Inhibitor potency and assay conditions: A case study on SARS-CoV-2 main protease
por: Behnam, Mira A. M., et al.
Publicado: (2021)

Insect protease inhibitors; promising inhibitory compounds against SARS-CoV-2 main protease
por: Hemmati, Seyed Ali, et al.
Publicado: (2022)

Development of a simple and miniaturized sandwich-like fluorescence polarization assay for rapid screening of SARS-CoV-2 main protease inhibitors
por: Yan, Gangan, et al.
Publicado: (2021)

Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors
por: Ma, Chunlong, et al.
Publicado: (2021)

Computational study on peptidomimetic inhibitors against SARS-CoV-2 main protease
por: Somboon, Tuanjai, et al.
Publicado: (2021)

Potential SARS-CoV-2 main protease inhibitors
por: Banerjee, Riddhidev, et al.
Publicado: (2021)

Developing inhibitors of the SARS-CoV-2 main protease
por: Seitz, Christian, et al.
Publicado: (2022)

Allosteric inhibitors of the main protease of SARS-CoV-2
por: Samrat, Subodh Kumar, et al.
Publicado: (2022)

Structure of SARS-CoV-2 main protease in the apo state
por: Zhou, Xuelan, et al.
Publicado: (2020)

Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors
por: Li, Zhe, et al.
Publicado: (2021)

Factual insights of the allosteric inhibition mechanism of SARS-CoV-2 main protease by quercetin: an in silico analysis
por: Verma, Shalja, et al.
Publicado: (2021)

In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus
por: Eleftheriou, Phaedra, et al.
Publicado: (2020)

Rutin Is a Low Micromolar Inhibitor of SARS-CoV-2 Main Protease 3CLpro: Implications for Drug Design of Quercetin Analogs
por: Rizzuti, Bruno, et al.
Publicado: (2021)

Biochemical screening for SARS-CoV-2 main protease inhibitors
por: Coelho, Camila, et al.
Publicado: (2020)

Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors
por: Huff, Sarah, et al.
Publicado: (2021)

Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease
por: Katagishi, Daiki, et al.
Publicado: (2023)

Potent and biostable inhibitors of the main protease of SARS-CoV-2
por: Tsuji, Kohei, et al.
Publicado: (2022)

The SARS-CoV-2 main protease induces neurotoxic TDP-43 cleavage and aggregates
por: Yang, Jiaxin, et al.
Publicado: (2023)

Identification of lactoferrin-derived peptides as potential inhibitors against the main protease of SARS-CoV-2
por: Zhao, Wenzhu, et al.
Publicado: (2022)

Discovery of potent benzoxaborole inhibitors against SARS-CoV-2 main and dengue virus proteases
por: Kühl, Nikos, et al.
Publicado: (2022)

In vitro and in vivo evaluation of the main protease inhibitor FB2001 against SARS-CoV-2
por: Shang, Weijuan, et al.
Publicado: (2022)

Potential Resistance of SARS-CoV-2 Main Protease (Mpro) against Protease Inhibitors: Lessons Learned from HIV-1 Protease
por: Mótyán, János András, et al.
Publicado: (2022)

High-throughput screening and evaluation of repurposed drugs targeting the SARS-CoV-2 main protease
por: Li, Yan, et al.
Publicado: (2021)

Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir
por: Bai, Yu, et al.
Publicado: (2021)

The main protease of SARS-CoV-2 downregulates innate immunity via a translational repression
por: Liang, Weifeng, et al.
Publicado: (2023)

Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2
por: Abel, Renata, et al.
Publicado: (2020)

A cyclic peptide inhibitor of the SARS-CoV-2 main protease
por: Kreutzer, Adam G., et al.
Publicado: (2021)

Fragment-based inhibitor design for SARS-CoV2 main protease
por: Andola, Priyanka, et al.
Publicado: (2022)

Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
por: Kuang, Yi, et al.
Publicado: (2023)

Multicomponent Synthesis of the SARS-CoV-2 Main Protease Inhibitor Nirmatrelvir
por: Preschel, H. Daniel, et al.
Publicado: (2023)

Computational estimation of potential inhibitors from known drugs against the main protease of SARS-CoV-2
por: Tam, Nguyen Minh, et al.
Publicado: (2021)

Discovery of inhibitors against SARS-CoV-2 main protease using fragment-based drug design
por: Shao, Hai Ping, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hik7fsjiodn61ssl0nnmkcpjod